Streetbeat News

Equity Actions

GLW

Seven analysts have recently provided their ratings on Corning (NYSE:GLW), with a mix of opinions. The average 12-month price target is $32.43, down 10.64% from the previous $36.29. Analysts from UBS, JP Morgan, Citigroup, Barclays, Oppenheimer, Morgan Stanley, and Deutsche Bank have adjusted their price targets and ratings, reflecting a cautious outlook. Corning's financial health shows a strong market position with a high market cap and net margin, but revenue decline and high debt-to-equity ratio present challenges.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 7:00 pm

SLG

SL Green Realty (NYSE:SLG) has been evaluated by 10 analysts over the last three months, with ratings ranging from bullish to bearish. The average 12-month price target is $42.7, up 5.96% from the previous $40.30. Analysts from firms like Goldman Sachs, Piper Sandler, Barclays, BMO Capital, and Truist Securities have updated their ratings and price targets, reflecting changes in market dynamics and company performance. SL Green Realty, a large Manhattan property owner, has seen a -18.47% decline in revenue growth and has a net margin of -13.84%, ROE of -0.62%, and ROA of -0.24%, with a debt-to-equity ratio of 1.14.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 7:00 pm

ACRS

Aclaris Therapeutics (NASDAQ:ACRS) has received mixed ratings from 4 analysts in the last three months, with 2 bullish and 2 indifferent ratings. The average 12-month price target is now $5.25, a significant drop from the previous $21.67. Analysts from HC Wainwright & Co. and Stifel have maintained and lowered their price targets, respectively, reflecting changes in market dynamics and company performance. Aclaris is a clinical-stage biopharmaceutical company with a focus on immuno-inflammatory diseases. Financially, the company has seen a -51.19% decline in revenue growth and has a net margin of -315.24%, with an ROE of -17.41% and an ROA of -12.89%. The company has no debt with a debt-to-equity ratio of 0.0.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 7:00 pm

ORAN

Orange Inc. (NYSE:ORAN) saw a 1.04% increase in its share price to $11.68. Despite a monthly decrease of 1.19%, the stock has risen 7.34% over the past year. The P/E ratio of Orange is 17.34, compared to the industry average of 54.64, which may suggest undervaluation or potentially weaker growth prospects.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 7:00 pm

TEAM

Atlassian (NYSE:TEAM) has seen a 23.58% increase in short interest since its last report, with 4.05 million shares sold short, representing 2.62% of available shares. The short interest is below the peer group average of 3.29%. While high short interest can indicate bearish sentiment, it does not necessarily predict a near-term price drop.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 6:30 pm

GMED

Six analysts have recently updated their ratings on Globus Medical (NYSE:GMED), with a mix of bullish, somewhat bullish, and indifferent stances. The average 12-month price target is now $63.33, up from $59.50, with individual targets ranging from $53.00 to $75.00. Analyst actions include maintaining, raising, and lowering ratings and price targets. Globus Medical, a medical device company, has shown a significant revenue growth rate of 50.95% as of September 30, 2023, but has below-average net margin and ROE/ROA compared to the industry. The company's debt-to-equity ratio is healthy at 0.12.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 6:00 pm

CTVA

Analysts have recently adjusted their ratings and price targets for Corteva (NYSE:CTVA), showing a negative shift in sentiment. The average 12-month price target is now $59.92, down 13.37% from previous estimates. Multiple analysts from firms such as UBS, Berenberg, and Morgan Stanley have lowered their price targets, reflecting changes in market conditions and company performance. Corteva's financial indicators show a decline in revenue growth, below-average net margin and ROE, and a conservative debt management approach. The company, a leader in seed and crop chemicals, was spun off from DowDuPont in 2019.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 6:00 pm

MIRM

Mirum Pharmaceuticals (NASDAQ:MIRM) has received mixed analyst ratings over the past three months, with 12 analysts offering a range of bullish to bearish perspectives. The average 12-month price target is $58.5, with a high of $77.00 and a low of $37.00. However, there has been a 17.89% decrease in the average price target, indicating a negative shift in sentiment. Analysts from firms like JMP Securities, Raymond James, HC Wainwright & Co., Cantor Fitzgerald, JP Morgan, Morgan Stanley, and Evercore ISI Group have provided various ratings and price target adjustments. Mirum Pharmaceuticals is a biopharmaceutical company with a focus on rare and orphan diseases, and its product Livmarli is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). The company has shown a revenue growth rate of 154.13% as of September 30, 2023, but faces challenges with a net margin of -49.42% and a debt-to-equity ratio of 1.14.

Portfolio Pulse from Benzinga Insights

January 11, 2024 | 6:00 pm

TLRY

Tilray Brands, Inc. (NASDAQ:TLRY) stock has fallen over 18% in the past five days. The drop follows an SEC filing revealing Tilray's acquisition of a promissory note from Double Diamond Holdings Ltd. for $26.1 million, compensated with over 12 million shares. Additionally, Tilray's Q2 financial results showed flat earnings per share, a 95% decrease YoY, and sales that missed analyst estimates. The stock traded heavily with over 21.1 million shares, surpassing the 100-day average volume.

Portfolio Pulse from Erica Kollmann

January 11, 2024 | 5:37 pm

VVPR

VivoPower International's stock is trading higher following the achievement of milestones by its Tembo subsidiary, which has led to a follow-on equity investment.

Portfolio Pulse from Benzinga Newsdesk

January 11, 2024 | 5:36 pm